Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

New Model Predicts Multiple Myeloma Survival Rates Will Significantly Improve in the Era of...

The unprecedented number of new drug approvals in multiple myeloma will lead to an increase in the number of patients living longer with myeloma,...
On location

Circulating Multiple Myeloma Cells a Useful, Non-Invasive Prognostic Marker for Plasma Cell Disorders

In patients with plasma cell disorders, disease burden assessments and molecular subtyping are typically performed by invasive bone marrow sampling. According to a study...
On location

Characterizing Patient-Reported Pain Management Strategies for Hemophilia

Patients with hemophilia have to manage both bleeding issues, and the consequent joint pain that follows recurrent hemarthrosis. Regional and national U.S. surveys have...
On location

Women With Clotting Factor Deficiencies Have Similar Excess Bleeding Risk, Regardless of Factor Levels

Women who have or are carriers for factor VIII (FVIII) or factor IX (FIX) deficiency often report excessive bleeding, though it is unclear how...
On location

Real-World Studies Report on the Use of Recombinant Porcine Factor VIII for Acquired Hemophilia...

Two retrospective studies presented at the Thrombosis and Hemostasis Societies of North America 2016 Summit provided real-world data on recombinant porcine factor VIII (rpFVIII)...
On location

IOM Workshop Tackles Immunotherapy Development, Use Issues

Earlier this year, the Institute of Medicine’s (IOM’s) National Cancer Policy Forum (NCPF), the National Academies of Sciences, Engineering, and Medicine, and the Health...
On location

Early Trial of Gene Therapy Option for Patients with Hemophilia B

Early results from an open-label phase I/II study of a new gene therapy product, named BAX335, offer promise of a long-term alternative to Factor...
On location

Triplet Combination of Daratumumab, Bortezomib, and Dexamethasone Improves Multiple Myeloma Survival

In the pivotal, randomized, controlled, phase III CASTOR study, adding daratumumab to bortezomib and dexamethasone (DVd) extended progression-free survival (PFS) and time to progression...
On location

SL-401 Improves Overall Response Rate for Blastic Plasmacytoid Dendritic Cell Neoplasm

CHICAGO--Early results from the lead-in phase of an ongoing phase II trial of SL-401 show high rates of overall response and complete response in...
On location

HOVON Trial: Hematopoietic Cell Transplant Superior to Novel Agents in Multiple Myeloma

CHICAGO--New data from the large, randomized, phase III HOVON trial suggest that upfront autologous hematopoietic cell transplantation (AHCT) should still be the treatment of...
Advertisement

Current Issue

October 2020 Volume 6, Issue 12

This issue examines racism in the U.S. health care system, discusses the FDA's newly loosened blood donation restrictions, and more.

Block title